MedinCell is trading at 34.39 as of the 5th of February 2026. This is a No Change since the beginning of the trading day. The stock's lowest day price was 34.39. MedinCell has about a 21 % chance of experiencing some form of financial distress in the next two years of operation and had a somewhat fair performance during the last 90 days. The performance scores are derived for the period starting the 7th of November 2025 and ending today, the 5th of February 2026. Click here to learn more.
It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception mdc-ANG for CNS related treatments mdc-ELK for depression and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. The company has 25.22 M outstanding shares. More on MedinCell SA
MedinCell SA [MDCLF] is a Pink Sheet which is traded between brokers as part of OTC trading. The company currently falls under 'Small-Cap' category with a current market capitalization of 244.65 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate MedinCell's market, we take the total number of its shares issued and multiply it by MedinCell's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. MedinCell SA classifies itself under Healthcare sector and is part of Biotechnology industry. The entity has 25.22 M outstanding shares.
MedinCell SA has accumulated about 34.39 M in cash with (21.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.38.
Check MedinCell Probability Of BankruptcyOwnership AllocationMedinCell SA maintains a total of 25.22 Million outstanding shares. MedinCell SA holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check MedinCell Ownership Details
About 48.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.88. MedinCell SA had not issued any dividends in recent years. The entity had 50:1 split on the 16th of March 2017. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception mdc-ANG for CNS related treatments mdc-ELK for depression and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. Medincell is traded on OTC Exchange in the United States.The quote for MedinCell SA is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To find out more about MedinCell SA contact Christophe Douat at 33 4 67 02 13 67 or learn more at https://www.medincell.com.
MedinCell SA Investment Alerts
MedinCell SA is way too risky over 90 days horizon
MedinCell SA appears to be risky and price may revert if volatility continues
The company reported the revenue of 4.09 M. Net Loss for the year was (24.81 M) with profit before overhead, payroll, taxes, and interest of 4.09 M.
MedinCell SA has accumulated about 34.39 M in cash with (21.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.38.
Roughly 48.0% of the company outstanding shares are owned by corporate insiders
MedinCell Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 244.65 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate MedinCell's market, we take the total number of its shares issued and multiply it by MedinCell's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Technical Drivers
As of the 5th of February, MedinCell secures the Risk Adjusted Performance of 0.1004, mean deviation of 11.72, and Standard Deviation of 48.34. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of MedinCell SA, as well as the relationship between them. Please verify MedinCell SAmean deviation, variance, as well as the relationship between the Variance and maximum drawdown to decide if MedinCell SA is priced some-what accurately, providing market reflects its recent price of 34.39 per share. Given that MedinCell SA has variance of 2336.49, we recommend you to check MedinCell's last-minute market performance to make sure the company can sustain itself at a future point.
The output start index for this execution was zero with a total number of output elements of sixty-one. MedinCell SA Inverse Tangent Over Price Movement function is an inverse trigonometric method to describe MedinCell price patterns.
MedinCell Predictive Daily Indicators
MedinCell intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of MedinCell pink sheet daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
MedinCell's time-series forecasting models are one of many MedinCell's pink sheet analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary MedinCell's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Our tools can tell you how much better you can do entering a position in MedinCell without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.
Did you try this?
Run Global Markets Map Now
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Other Information on Investing in MedinCell Pink Sheet
MedinCell financial ratios help investors to determine whether MedinCell Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in MedinCell with respect to the benefits of owning MedinCell security.